The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
about
Safety profile of biological therapies for treating rheumatoid arthritis.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.
P2860
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The Risk of Progressive Multif ...... ra: Prevention and Management.
@en
The Risk of Progressive Multif ...... ra: Prevention and Management.
@nl
type
label
The Risk of Progressive Multif ...... ra: Prevention and Management.
@en
The Risk of Progressive Multif ...... ra: Prevention and Management.
@nl
prefLabel
The Risk of Progressive Multif ...... ra: Prevention and Management.
@en
The Risk of Progressive Multif ...... ra: Prevention and Management.
@nl
P2093
P1476
The Risk of Progressive Multif ...... ra: Prevention and Management.
@en
P2093
Cassandra M Calabrese
Eamonn S Molloy
Leonard H Calabrese
P304
P356
10.1016/J.RDC.2016.09.009
P577
2017-02-01T00:00:00Z